e-academy CEO Appointed to Telefilm Canada

The Honourable James Moore, Minister of Canadian Heritage and Official Languages, today announced the appointment of Ram Krishna Raju as a member of Telefilm Canada.

"I am delighted that Mr. Raju has accepted this appointment," said Minister Moore. "Telefilm Canada will undoubtedly benefit from his strong leadership, dynamism, extensive knowledge, and experience in the digital and information technology industry."

Call for Applications - Innovacorp Board Members

Innovacorp helps high potential early stage Nova Scotia companies commercialize their technologies and succeed in the global marketplace. Our High Performance Incubation (HPi)™ business model incorporates incubation infrastructure, business mentoring, and seed and venture capital investment. HPi is recognized internationally as a best practice technology commercialization approach.

Immunovaccine Signs Research Agreement with Dana-Farber Cancer Institute

Immunovaccine Inc.(TSX-V:IMV), a vaccine development company, announced today that it has signed a collaborative agreement with the Dana-Farber Cancer Institute, a principal teaching affiliate of the Harvard Medical School.

The research collaboration involves formulating Dana-Farber’s HIV protein antigens in Immunovaccine’s DepoVax™ vaccine enhancement and delivery platform. The goal of this preclinical research is to establish whether this novel vaccine formulation will induce a stronger immune response.

Innovacorp Finalist for International Business Incubation Award

Innovacorp has once again been named one of two finalists in the National Business Incubation Association (NBIA) Incubation Program of the Year - 2010 competition.

The award recognizes the world's best methods to help new companies commercialize innovations and overcome hurdles to business growth. Innovacorp is a finalist alongside Emerging Technology Centers in Baltimore, Maryland.

Immunovaccine Begins Patient Recruitment for Phase I Trial of DPX-0907 Cancer Vaccine

Immunovaccine Inc. (TSX-V: IMV) today announced that it has started screening patients for its Phase I clinical trial, investigating the company’s therapeutic cancer vaccine, DPX-0907, as a treatment for patients with advanced stage breast, ovarian and prostate cancer. The primary goal of the trial is to establish the safety of the vaccine candidate which includes the DepoVax™ delivery platform. Secondary goals include an evaluation of dosing and an assessment of immune response.

EastMed Achieves National Health Coverage for uresta® Continence Care Product

EastMed Inc., an Atlantic Canadian medical manufacturing company that caters specifically to women's health and wellness, now has national health coverage for the uresta® Continence Care product.

Blue Cross recently agreed to cover the uresta® Continence Care product, joining other insurers Great West Life, ManuLife, and SunLife and ensuring national health coverage with all the major health insurers for this innovative women’s health product.


Subscribe to Innovacorp RSS